Gurevičienė, G. 2019. PD-L1 INHIBITOR PEMBROLIZUMAB – FOR FIRST LINE ADVANCED NON-SMALL CELL LUNG CANCER THERAPY. Pulmonology and allergology. 3, 2 (Sep. 2019), 177-182. DOI:https://doi.org/10.37499/PIA.136.